Press Enter to search · Esc to close
The shots that started as diabetes medicine and became weight-loss icons are quietly rewriting their own job description. The 2025 evidence points to a multi-organ story — with caveats worth knowing.
Semaglutide and tirzepatide started as obesity treatments. A wave of moderate-quality evidence is pushing them toward something bigger — and asking new questions about inflammation, the heart, and even cancer.
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.